News Formal

Psychedelic Stocks Tank After FDA Advisors Shoot Down MDMA Therapy For PTSD

  • 📰 Forbes
  • ⏱ Reading Time:
  • 42 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 51%
  • Publisher: 53%

Mdma News

Psychedelics,FDA,Ptsd

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Musk Says ‘Freedom Of Speech Is Worth Fighting For’ As Australia Drops Legal Fight Over Church Stabbing Videos On X

WNBA Sky-Fever Game With Controversial Foul On Caitlin Clark Drew 1.5 Million Viewers—Nearly 350% Above 2023 Regular Season ViewershipShares for companies focused on psychedelic medicines plummeted during premarket trading on Wednesday after independent experts advised the Food and Drug Administrationand stimulant drug MDMA, commonly known as ecstacy or molly, for post-traumatic stress disorder, a major setback for those hoping to open a new era of medicine for the often-outlawed substances.

Others hit include Relmada Therapeutics, which targets central nervous system conditions and was down around 5%, and Dublin drug developer GH Research, down around 3.5%.whether psychedelics can treat neurological diseases, appears to be a notable exception, with shares up nearly 2% during premarket trading.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 394. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Psychedelic Stocks Tank After FDA Advisors Shoot Down MDMA Therapy For PTSDRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Source: ForbesTech - 🏆 318. / 59 Read more »

Hims & Hers CEO walks back supporting campus protests after company stocks tankThe CEO had initially said that there are 'plenty' of companies ready to hire the protesters, 'regardless of university discipline.
Source: dcexaminer - 🏆 6. / 94 Read more »

Buffett's 2024 Investment Wisdom: Psychology Matters As Much As FinancialsI am the editor of three Forbes investment newsletters: Forbes Dividend Investor, Forbes Billionaire Investor and covered call writing advisory service, Forbes Premium Income Report. Prior to joining Forbes in 2001, I was a producer and reporter at CNN Financial News, focusing on stories about entrepreneurship.
Source: Forbes - 🏆 394. / 53 Read more »